Brief: CTI BioPharma Q1 Loss Per Share $0.23

CTI Biopharma

01/06/2021 21:26

June 1 (Reuters) - CTI Biopharma Corp  CTIC.O :
    * CTI BIOPHARMA REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS
    * Q1 LOSS PER SHARE $0.23
    * SAYS NDA FOR PACRITINIB FOR TREATMENT OF MYELOFIBROSIS
PATIENTS
WITH SEVERE THROMBOCYTOPENIA ACCEPTED WITH PRIORITY REVIEW BY
FDA
    * SAYS COMMERCIALIZATION ACTIVITIES ON TRACK TO SUPPORT A
POTENTIAL APPROVAL AND LAUNCH OF PACRITINIB IN UNITED STATES IN
2021

Source text for Eikon:  ID:nPn8S8qqFa 
Further company coverage:  CTIC.O 

 ((Reuters.Briefs@thomsonreuters.com;))